Lyudmila Bazhenova

Dr. Lyudmila Bazhenova, co-chair on the ASCO Living Guideline for lung cancer therapy, dives into the latest updates on treating stage IV NSCLC without driver alterations. She outlines new second-line treatment recommendations, particularly highlighting trastuzumab durextecan for HER2 overexpression. The conversation also touches on the differences in HER2 testing criteria between lung and breast cancers and the importance of ongoing clinical trials like Harmony 2 and LUNAR that shape these guidelines.